Riskpilot← Back to searchSign inGet full accessZP GENERAL PARTNER 1 ApS
APSActiveCVR 36402660Sydmarken 11Research and experimental development on natural sciences and engineering · NACE 7210Est. 2014— employees
Revenue 2024
DKK 5K
+67% vs 2023
EBITDA margin
-200.0%
0% vs 2023
Equity ratio
22.5%
Financial strength
Net profit 2024
DKK -14K
-27% vs 2023
| Revenue | DKK 5K | +67% |
| EBITDA | DKK -10K | +0% |
| Net profit | DKK -14K | -27% |
| Total assets | DKK 89K | +93% |
| Equity | DKK 20K | -41% |
| Employees | — | — |
Legal name
ZP GENERAL PARTNER 1 ApS
CVR number
36402660
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
10. oktober 2014
Share capital
DKK 100.000
Employees
—
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af to direktører.
Company purpose
Selskabets formål er at være komplementar i ZP Holding SPV K/S.
Address
Sydmarken 11
Email
info@zealandpharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | — | — | — | — | 346 | 1 | 3 | 3 | 5 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | 0 | -0 | -0 | -2 | -1 | -2 | 345 | -1 | -12 | -10 | -10 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | 0 | -0 | -0 | -2 | -1 | -2 | 345 | -1 | -12 | -10 | -10 |
| Net financials | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -20 | -1 | -4 |
| Profit before tax | 0 | -0 | -0 | -2 | -1 | -2 | 345 | -1 | -32 | -11 | -14 |
| Tax | -0 | -0 | -0 | -0 | -0 | -0 | 76 | -0 | -0 | -0 | -0 |
| Net profit | 0 | -0 | -0 | -2 | -1 | -2 | 269 | -1 | -32 | -11 | -14 |
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 0 | 0 | 0 | 6 | 3 | 14 | 779 | 196 | 6.042 | 46 | 89 |
| Equity | 0 | 0 | 0 | 3 | 2 | 12 | 609 | 12 | 45 | 34 | 20 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 0 | 0 | 3 | 1 | 2 | 170 | 184 | 5.997 | 12 | 69 |
| Total debt | 0 | 0 | 0 | 3 | 1 | 2 | 170 | 184 | 5.997 | 12 | 69 |
EBITDA margin
-200.0%
This company
15.8%
Market median
-1366% vs market
20142024
Equity ratio
22.5%
This company
38.2%
Market median
-41% vs market
20142024
Return on equity
-70.0%
This company
18.4%
Market median
-480% vs market
20142024
Net profit margin
-280.0%
This company
8.1%
Market median
-3557% vs market
20142024
Asset turnover
0.06×
This company
1.12×
Market median
-95% vs market
20142024
Debt / equity
3.45×
This company
0.62×
Market median
-456% vs market
20142024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-10-10 – 2014-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
MD Management | Management | 2019 | — | — |
MP Management | Management | 2014 | — | — |
DH Management | Management | 2014 | — | — |
ED Management | Management | 2019 | — | — |
AS Management | Management | 2022 | — | — |
IM Management | Management | 2019 | — | — |
HW Management | Management | 2022 | — | — |
ED Management | Management | 2019 | — | — |
BM Management | Management | 2015 | — | — |
LR Management | Management | 2022 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
ZEALAND PHARMA A/S | Company | 100.0% | 100.0% | 2014 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
ZEALAND PHARMA A/S
ZP GENERAL PARTNER 1 ApS Board members of ZP GENERAL PARTNER 1 ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Matthew Donald Dallas | Management | 0 companies |
| Mats Peter Blom | Management | 0 companies |
| David Horn Solomon | Management | 0 companies |
| Emmanuel Dulac | Management | 0 companies |
| Adam Sinding Steensberg | Management | 0 companies |
| Ivan Mourits Møller | Management | 0 companies |
| Henriette Wennicke | Management | 0 companies |
| Emmanuel Dulac | Management | 0 companies |
| Britt Meelby Jensen | Management | 0 companies |
| Lykke Rømer | Management | 0 companies |